

8/5/5

DIALOG(R) File 351:Derwent WPI
(c) 2001 Derwent Info Ltd. All rts. reserv.

009565138

WPI Acc. No: 1993-258686/199332

XRAM Acc No: C93-114929

New granulocyte colony stimulating factor fusion proteins - contg.
stabilising protein, for treating leukopenia, leukaemia, etc.

Patent Assignee: RHONE POULENC RORER SA (RHON); RHONE-POULENC RORER SA
(RHON)

Inventor: YEH P

Number of Countries: 022 Number of Patents: 007

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9315211	A1	19930805	WO 93FR86	A	19930128	199332 B
FR 2686900	A1	19930806	FR 921065	A	19920131	199344
FI 9403564	A	19940729	WO 93FR86	A	19930128	199437
			FI 943564	A	19940729	
NO 9402858	A	19940801	WO 93FR86	A	19930128	199438
			NO 942858	A	19940801	
EP 624200	A1	19941117	EP 93904130	A	19930128	199444
			WO 93FR86	A	19930128	
JP 7503844	W	19950427	JP 93512987	A	19930128	199525
			WO 93FR86	A	19930128	
US 5665863	A	19970909	WO 93FR86	A	19930129	199742
			US 94256938	A	19940727	

Priority Applications (No Type Date): FR 921065 A 19920131

Cited Patents: DE 3723781; EP 361991; EP 364980; EP 395918; EP 401384; WO 9013653

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9315211 A1 F 36 C12N-015/62

Designated States (National): CA FI JP NO US

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

FR 2686900 A1 26 C12P-021/02

EP 624200 A1 F C12N-015/62 Based on patent WO 9315211

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

JP 7503844 W C12N-015/09 Based on patent WO 9315211

US 5665863 A 32 C12N-015/27 Based on patent WO 9315211

FI 9403564 A C12N-000/00

NO 9402858 A C12N-000/00

Abstract (Basic): WO 9315211 A

New recombinant polypeptides (I) comprise an active portion (II) coupled to a protein stabilising structure (III), where (II) comprises all or part of human granulocyte colony stimulating factor (G-CSF) or a G-CSF variant.

Also claimed are: (1) nucleotide sequences coding for (I); (2) expression cassettes contg. such a nucleotide sequence under the control of a transcription initiation region and opt. a transcription termination region; (3) self-replicating plasmids contg. such expression cassettes; and (4) recombinant eukaryotic or prokaryotic cells contg. such sequences, cassettes or plasmids.

USE/ADVANTAGE - (I) may be used to treat diseases requiring an increase in granulocyte count and/or activity, esp. leucopenia and certain forms of leukaemia, or to stimulate the immune system during transplantation (e.g. of bone marrow) or after cancer chemotherapy. (I) are capable of maintaining G-CSF activity for long periods *in vivo*. E.g., a specifically disclosed polypeptide (HSA-G-CSF) has lower *in vitro* activity than native G-CSF *in vitro* but comparable activity *in vivo*.

Dwg.0/8

Title Terms: NEW; GRANULOCYTE; COLONY; STIMULATING; FACTOR; FUSE; PROTEIN; CONTAIN; STABILISED; PROTEIN; TREAT; LEUKOPENIA; LEUKAEMIA

Derwent Class: B04; D16

International Patent Class (Main): C12N-000/00; C12N-015/09; C12N-015/27; C12N-015/62; C12P-021/02

International Patent Class (Additional): A61K-037/02; A61K-038/00; C07K-013/00; C07K-014/53; C12N-001/19; C12N-015/14; C12N-015/81; C12R-001-645

File Segment: CPI